文献速递外周动脉疾病

新型螺旋自膨式镍钛合金支架治疗股腘动脉闭塞性疾病的有效性与安全性

Efficacy and Safety of a Novel Helical Self-Expanding Nitinol Stent for Femoropopliteal Artery Obliterans Disease.
PubMed 文献 · Ann Vasc Surg · 2020-09-04

本研究回顾性分析了48例患者(50条肢体)使用Smartflex支架治疗股腘动脉闭塞性病变的结果。平均病变长度18.2 cm,多数为慢性完全闭塞(94%)和严重钙化(32%)。1年原发通畅率83.3%,免于临床驱动的靶病变血运重建率88.1%,无支架断裂或扭结。结论认为该支架安全有效,尤其在长段和膝上病变中表现良好。

要点

  • Smartflex支架治疗股腘动脉长段闭塞病变1年原发通畅率达83.3%。
  • 1年内免于临床驱动的靶病变血运重建率为88.1%。
  • 无支架断裂或扭结发生,安全性良好。

核心结论

  • 使用Smartflex支架治疗股腘动脉疾病安全有效,在长段和膝上病变中表现良好。

研究设计与样本

  • 回顾性分析2016年6月至2019年5月单中心48例患者(50条肢体)的股腘动脉闭塞性疾病,使用Smartflex支架,随访1、3、6、12个月及之后每年。

主要发现

  • 共植入88枚Smartflex支架(每肢体1.76枚),平均病变长度18.2±8.5 cm,平均支架长度22.3±9.9 cm。
  • 平均随访16.4±8.2个月,1年原发通畅率83.3%,1年免于CD-TLR率88.1%,二次通畅率94%。
  • 90%患者踝肱指数改善(术前0.47±0.13,术后0.84±0.16),无支架断裂和扭结。

关键数值与推荐

  • 病变特征:TASC II C级占26%,D级占42%;慢性完全闭塞占94%(42/50例病变?原文42(94%)),严重钙化占32%。
  • 临床分型:Rutherford III级占82%,IV级占10%,V级占8%。

临床怎么用

  • 对于股腘动脉长段、慢性完全闭塞或严重钙化病变,可考虑使用Smartflex支架,但需注意本研究为回顾性单中心设计。

局限性

  • 回顾性研究,样本量较小(48例患者),随访时间较短(平均16.4个月),缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to evaluate the efficacy and safety of a novel self-expanding nitinol stent (Smartflex stent) in femoropopliteal artery obliterans disease. METHODS: From June 2016 to May 2019, patients with atherosclerotic occlusion disease of the superficial femoral and popliteal arteries using the Smartflex stents were retrospectively analyzed in our institution. Patients were monitored at 1, 3, 6, and 12 months and annually thereafter. The main characteristics of the diseased vessels, perioperative and follow-up outcome were evaluated. Kaplan-Meier method was used to assess patency rate and the rate of freedom from clinically driven target lesion revascularization (CD-TLR). RESULTS: A total of 50 limbs from 48 patients (mean age 69.4 ± 8.95 years; 38 men) were included. Eighty-eight Smartflex stents (1.76 stents per limb) were deployed successfully. Of the study patients, 82% had claudication (Rutherford III), 10% had rest pain (Rutherford IV), and 8% had tissue loss (Rutherford V). Trans-Atlantic Inter-Society Consensus II C and D lesions were 26% and 42%, respectively. The mean lesion length was 18.2 ± 8.5 cm and the mean stented length was 22.3 ± 9.9 cm. The average follow-up time was 16.4 ± 8.2 months. Of these lesions, 42 (94%) were chronic total occlusions and 16 (32%) were severely calcified. The primary patency rate at 1 year per Kaplan-Meier estimating, the rate of freedom from CD-TLR at 1 year, and the second patency rate was 83.3%, 88.1%, and 94%, respectively. Among them, 90% patients had improved ankle-brachial indexes (0.47 ± 0.13 before and 0.84 ± 0.16 after). No stent fractures and kinking were identified. CONCLUSIONS: Stenting of the femoropopliteal artery diseases using the Smartflex stent appeared to be safe and effective. It performed well in long-segment and above knee joint lesions.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lin Y, Hong S, Fu W, et al. Efficacy and Safety of a Novel Helical Self-Expanding Nitinol Stent for Femoropopliteal Artery Obliterans Disease. Ann Vasc Surg. 2020. PMID: 32891741. doi:10.1016/j.avsg.2020.08.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。